Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Invest Ophthalmol Vis Sci. 2014 Aug 19;55(9):5871-7. doi: 10.1167/iovs.14-14481.
We characterized antigen-presenting cell (APC)-relevant chemokine receptor expression in dry eye disease (DED), and investigated the effect of topical CC chemokine receptor (CCR)-7 blockade specifically on Th17 cell immunity and dry eye disease severity.
We induced DED in female C57BL/6 mice. Chemokine receptor expression by corneal APCs was characterized using immunohistochemistry. To determine the functional role of CCR7 in DED, mice were treated topically with either anti-CCR7, a control isotype antibody, or left untreated, and clinical disease severity, Th17 responses, and molecular markers of DED were quantified.
Frequencies of CD11b(+) cells and their chemokine expression were increased in the cornea of DED mice. Mice treated topically with anti-CCR7 antibody displayed a significant reduction in clinical disease severity and Th17 response compared to the isotype and untreated groups. Topical CCR7 blockade was effective in ameliorating DED in its acute and chronic stages.
Our findings suggest that CCR7-mediated trafficking of APCs drives the induction and maintenance of Th17 immunity in DED and that CCR7 blockade is effective in suppressing the immunopathogenic mechanisms in DED.
我们描述了干眼症(DED)中抗原呈递细胞(APC)相关趋化因子受体的表达,并研究了局部 C 趋化因子受体(CCR)-7 阻断对 Th17 细胞免疫和干燥眼病严重程度的影响。
我们在雌性 C57BL/6 小鼠中诱导 DED。使用免疫组织化学方法描述角膜 APC 上趋化因子受体的表达。为了确定 CCR7 在 DED 中的功能作用,我们用抗 CCR7、对照同型抗体或未处理的方式对小鼠进行局部治疗,并对临床疾病严重程度、Th17 反应和 DED 的分子标志物进行定量。
DED 小鼠角膜中 CD11b(+)细胞及其趋化因子表达的频率增加。与同型和未处理组相比,用抗 CCR7 抗体局部治疗的小鼠临床疾病严重程度和 Th17 反应明显降低。CCR7 阻断在改善 DED 的急性和慢性阶段均有效。
我们的发现表明,CCR7 介导的 APC 转运驱动了 Th17 免疫在 DED 中的诱导和维持,而 CCR7 阻断可有效抑制 DED 中的免疫发病机制。